It was suggested that substances with the ability to activate USP9X or inhibit α-synuclein mono-ubiquitination could facilitate autophagic degradation of α-synuclein and function as therapeutics in cases of α-synuclein-associated PD [79]. This evidence concerns the gene SNCA and Parkinson disease.